Literature DB >> 26449843

New Options in Constipation Management.

Mellar Davis1,2,3, Pamela Gamier4,5,6.   

Abstract

Constipation is common in the general population and for those on opioids and/or who are suffering from advanced cancer. Self-management consists of dietary changes, exercise, and laxatives. However, responses to self-management efforts are often inadequate to relieve the subjective and objective experience of constipation. Multiple new anti-constipating medications have recently been tested in randomized trials and the following are available commercially: probiotics, prucalopride, lubiprostone, linaclotide, elobixibat, antidepressants, methylnaltrexone, alvimopan, and naloxegol. This review will discuss the evidence-based benefits of these medications and outline an approach to managing constipation.

Entities:  

Keywords:  Antagonist; Constipation; Linaclotide; Lubiprostone; Mu receptor; Probiotics; Prokinetics; Transporter

Mesh:

Substances:

Year:  2015        PMID: 26449843     DOI: 10.1007/s11912-015-0481-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  103 in total

Review 1.  Chronic constipation.

Authors:  Anthony Lembo; Michael Camilleri
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

2.  Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome.

Authors:  Ruchit Sood; Alexander C Ford
Journal:  Ther Adv Chronic Dis       Date:  2013-11       Impact factor: 5.091

3.  [Characterization of intestinal function and diagnosis of irritable bowel syndrome by surveys and questionnaires].

Authors:  D A Drossman
Journal:  Gastroenterol Clin Biol       Date:  1990

Review 4.  Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review.

Authors:  Jan Gaertner; Waldemar Siemens; Michael Camilleri; Andrew Davies; Douglas A Drossman; Lynn R Webster; Gerhild Becker
Journal:  J Clin Gastroenterol       Date:  2015-01       Impact factor: 3.062

Review 5.  Lubiprostone for the treatment of opioid-induced bowel dysfunction.

Authors:  Banny S Wong; Michael Camilleri
Journal:  Expert Opin Pharmacother       Date:  2011-03-09       Impact factor: 3.889

6.  Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors.

Authors:  Christel Rousseaux; Xavier Thuru; Agathe Gelot; Nicolas Barnich; Christel Neut; Laurent Dubuquoy; Caroline Dubuquoy; Emilie Merour; Karen Geboes; Mathias Chamaillard; Arthur Ouwehand; Greg Leyer; Didier Carcano; Jean-Frédéric Colombel; Denis Ardid; Pierre Desreumaux
Journal:  Nat Med       Date:  2006-12-10       Impact factor: 53.440

Review 7.  Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature.

Authors:  Davide Tassinari; Sergio Sartori; Emiliano Tamburini; Emanuela Scarpi; William Raffaeli; Paola Tombesi; Marco Maltoni
Journal:  J Palliat Med       Date:  2008-04       Impact factor: 2.947

Review 8.  Chronic metoclopramide therapy for diabetic gastroparesis.

Authors:  Paul F Lata; Denise L Walbrandt Pigarelli
Journal:  Ann Pharmacother       Date:  2003-01       Impact factor: 3.154

Review 9.  Clinical utility of naloxegol in the treatment of opioid-induced constipation.

Authors:  Heather C Bruner; Rabia S Atayee; Kyle P Edmonds; Gary T Buckholz
Journal:  J Pain Res       Date:  2015-06-12       Impact factor: 3.133

10.  Practical Methods to Assess Chronic Constipation.

Authors:  Kyung Ho Song
Journal:  J Neurogastroenterol Motil       Date:  2015-07-30       Impact factor: 4.924

View more
  2 in total

Review 1.  Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments.

Authors:  Rachel M McQuade; Vanesa Stojanovska; Raquel Abalo; Joel C Bornstein; Kulmira Nurgali
Journal:  Front Pharmacol       Date:  2016-11-03       Impact factor: 5.810

Review 2.  Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem.

Authors:  Stephanie C Yoon; Heather C Bruner
Journal:  Patient Prefer Adherence       Date:  2017-07-24       Impact factor: 2.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.